Hansoh Pharmaceutical Group Company Limited (FRA:3KY)

Market Cap	23.11B -2.8%
Revenue (ttm)	2.05B +20.5%
Net Income	860.57M +39.7%
EPS	0.14 +37.9%
Shares Out	n/a
PE Ratio	26.86
Forward PE	n/a
Dividend	0.05 (1.42%)
Ex-Dividend Date	Sep 22, 2026

Volume	n/a
Open	3.727
Previous Close	3.750
Day's Range	3.727 - 3.759
52-Week Range	3.093 - 4.800
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 26, 2026

About FRA:3KY

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and ...

• Industry: Pharmaceutical Preparations
• Founded: 1995
• Employees: 9,643
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 3KY

Financial Performance

In 2025, FRA:3KY's revenue was 15.03 billion, an increase of 22.57% compared to the previous year's 12.26 billion. Earnings were 5.56 billion, an increase of 27.07%.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Sep 18, 2026

Data Sources Report a data error